Every day, approximately 5,000 people in the United States are diagnosed with some form of liver disease. In many cases, this can be treated with medication and lifestyle changes. But in some cases, surgery is required to save the patient’s life. One such surgery is a hepaticojejunostomy (HJ), or “liver bypass”. HJ is a life-saving procedure that can restore normal functioning of the digestive system and provide relief from symptoms that come with certain types of liver diseases. In this blog article, we will discuss what you need to know about HJ—from its benefits to its risks—so you can make an informed decision if you ever need it.
A hepaticojejunostomy is a life-saving surgery that is used to treat patients with liver failure. The surgery involves attaching the patient's jejunum (a section of the small intestine) to the liver, which allows the liver to receive nutrients and blood from the intestine. The surgery is typically performed when other treatment options have failed and the patient's life is in danger.
The hepaticojejunostomy surgery is a complicated and risky procedure, but it can be successful in treating liver failure. The success of the surgery depends on many factors, including the severity of the liver failure, the health of the patient, and the experience of the surgeon. The surgery carries a risk of complications, such as infection, bleeding, and inflammation. Recovery from hepaticojejunostomy surgery can take several weeks or months.
Despite the risks, hepaticojejunostomy surgery can be a life-saving treatment for patients with liver failure.
There are two types of hepaticojejunostomy: an end-to-side and a side-to-side. Overall, the side-to-side is considered to be the better choice, as it results in fewer complications and a quicker recovery.
An end-to-side hepaticojejunostomy is when the jejunum (the second part of the small intestine) is attached to the side of the liver. This type of surgery is typically done when there is damage to the portal vein (the vein that brings blood from the intestines to the liver).
A side-to-side hepaticojejunostomy is when the jejunum is attached directly to the liver. This type of surgery is typically done when there is damage to both the portal vein and hepatic artery (the artery that brings oxygenated blood to the liver).
When deciding if hepaticojejunostomy is the right surgery for you, it is important to weigh the pros and cons of the procedure. Some of the advantages of hepaticojejunostomy include:
- Reduced risk of liver disease progression: By removing the bile duct obstruction, hepaticojejunostomy can help to prevent further damage to the liver.
- Improved quality of life: Many patients report feeling better after undergoing hepaticojejunostomy surgery. This improved quality of life may be due to a reduction in symptoms or an overall improvement in health.
- Increased life expectancy: Hepaticojejunostomy can extend a patient’s life by reducing the risk of liver failure and other complications associated with advanced liver disease.
There are also some potential disadvantages of hepaticojejunostomy to consider, such as:
- Complications: As with any surgery, there is always a risk of complications occurring during or after the procedure. Possible complications from hepaticojejunostomy include bleeding, infection, and bile leak.
- Cost: Hepaticojejunostomy is a complex surgery that typically requires a longer hospital stay and more postoperative care than simpler procedures. This can make the procedure quite costly.
After surgery, patients will be closely monitored in the intensive care unit (ICU) for the first 24-48 hours. During this time, they will be closely monitored for any signs of bleeding or infection. Once they are stable, they will be transferred to a regular hospital room. Recovery from surgery takes time, and patients will likely stay in the hospital for 7-10 days. During this time, they will gradually start to eat and drink again and begin to walk around. Physical therapy will help them regain their strength. Finally, they will be discharged home with instructions for follow-up care.
Hepaticojejunostomy is a life-saving surgery that is used to treat patients with liver failure. The surgery involves the removal of a section of the stomach, called the gastric fundus, and attaching it to the small intestine. This allows the blood to bypass the damaged liver and flow directly to the small intestine.
Recovery time from hepaticojejunostomy surgery is typically short, with most patients being discharged from the hospital within a week. However, it is important for patients to follow their surgeon's instructions carefully and take all prescribed medications in order to prevent any complications.
There are always risks and potential complications associated with any surgery, and a hepaticojejunostomy is no exception. The most common complication from this surgery is internal bleeding, which can be fatal. Other risks include infection, leakage from the incision site, and blockage of the bile duct.
Internal bleeding is the most serious and potentially life-threatening complication of a hepaticojejunostomy. It can occur immediately after surgery or days or weeks later. If internal bleeding occurs, it will usually require an emergency blood transfusion and re-admission to the hospital. Infection is another serious complication that can occur after any surgery. The risk of infection increases if the patient has diabetes or chronic liver disease. Leakage from the incision site can also occur, which can lead to infection or abscess formation. Blockage of the bile duct is another potential complication, which can cause pain, jaundice, or pancreatitis.
Hepaticojejunostomy is a major life-saving surgery that can save the lives of people with severe liver damage. Although it has many risks, its successes have been seen time and time again for those who are willing to make the decision to undergo this surgery.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
In leukemia, allogeneic HCT is beneficial following primary induction failure.
2.
Team finds broken 'brake' on cancer mutation machine.
3.
Omega Fatty Acid Changes Tied to Lower Proliferation Rate in Early Prostate Cancer
4.
Prostate cancer screening program beneficial in top decile of polygenic risk score
5.
Talk About Medication Costs, Bringing Back Touch, and Understanding From Dish Tumors.
1.
New Research on Craniopharyngioma
2.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
3.
A Closer Look at White Blood Cells in Urine: Uncovering the Causes and Treatments
4.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
5.
The Mysterious World of Petechiae: Exploring Causes and Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Navigating the Complexities of Ph Negative ALL - Part XV
5.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation